KVUE

#415
Kenvue Inc. Common Stock
17.4 6 USD
-1.24%
부문: 소비방어재
베이스: USD
수익 통화: USD
일일 변동 비율
17.42
17.68
년간 변동
0.18
19.18
일일 변동
-1.24%
월간 변동
+1.04%
6달 변화
+1.01%
년간 변동율
+15.78%
이전 종가
17.6 8
Open
17.6 0
저가
17.4 2
High
17.6 8
양
995
전체 차트 열기 Full chart

Financials

개요 성명 통계 배당금
4분기 연간
  • Market Capitalization 33.52 B
  • Employee 22 K
  • Founded 2022
  • CEO Kirk Perry
  • Website www.kenvue.com
  • Headquarter Delaware, United States
  • FIGI BBG01C79X561
  • Industry 가정 & 개인용품
총매출
순이익
주당 순이익(기본 EPS)
총부채
잉여 현금 흐름
현금 및 현금성 자산
주가수익비율
22.62
주가매출액비율
2.19
주당 배당금
0.82
배당수익률 %
4.8

Kenvue Inc. Common Stock

Kenvue Inc. is an American consumer health company. Formerly the Consumer Healthcare division of Johnson & Johnson, Kenvue owns well-known brands such as Aveeno, Band-Aid, Benadryl, Combantrin, Zyrtec, Johnson's, Listerine, Lactaid, Mylanta, Neutrogena, Trosyd, Calpol, Tylenol, and Visine. Kenvue is incorporated in Delaware and was originally headquartered in the Skillman section of Montgomery Township, New Jersey, before relocating to Summit, New Jersey. Johnson & Johnson announced in November 2021 that it would spin off its consumer health division as a separate company. The new company was named Kenvue in September 2022, and its initial public offering took place in May 2023, raising $3.8 billion in the largest U.S. IPO since 2021, with an initial valuation of about $41 billion. Johnson & Johnson initially retained more than 90% ownership before completing a full separation through a share exchange in July 2023. Kenvue was subsequently added to the S&P 500 Dividend Aristocrats index. CEO Thibaut Mongon initially led Kenvue, which employed about 22,200 people in 2022. Following Mongon’s termination in 2025, Kirk Perry was named interim CEO.

뉴스